Abstract
1316
Objectives After reviewing this presentation, attendeeswill be familiar with 1) the pathophysiologic basis of FDG uptake in malignant tumors, 2) the biologic and technical factors influencing the intensity of FDG signal and 3) the patterns of FDG uptake in inflammatory vs malignant tissue.
Methods In this presentation, we will describe 1) the effect of Glut (Glucose Transporter) expression, tumor cellularity and mucin production on PET signal intensity, 2) how differences in the expression of these factors between various sites of cancer within the same patient may cause differences in PET signal intensity, 3) the effect of serum glucose and insulin levels on tumor FDG uptake and overall image quality, 4) the relevance of serum glucose measurement prior to FDG injection, 5) the effect of lesion size on PET signal intensity, 6) the current role of SUV in clinical setting and research, 7) the effect of attenuation correction and motion on PET signal intensity and 8) how to differentiate between inflammation and malignancy on PET.
Results We will exemplify these aspects of PET imaging based on illustrative examples from our busy PET program.
Conclusions FDG PET is routinely used in cancer imaging. And yet, there is a wide range of recommendations regarding preparation and interpretation of FDG PET cancer studies. A better understanding of some basic concepts of PET scanning in general and FDG PET in particular will help to apply these recommendations more appropriately and tailor them to clinical scenarios at hand. RESEARCH SUPPORT: